{"id":"deoxycoformycin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia","Bone marrow depression","Breastfeeding (mother)","CNS Toxicity","Disease of liver","Infectious disease","Kidney disease","Leukopenia","Liver function tests abnormal","Low blood pressure","Neutropenic disorder","Pregnancy, function","Pulmonary edema","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1580","moleculeType":"Small molecule","molecularWeight":"268.27"},"aliases":["pentostatin, dCF"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Adenosine deaminase, Adenosine deaminase"},"_scrapedAt":"2026-03-28T05:01:42.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Hairy cell leukemia","diseaseId":"hairy-cell-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT05757310","phase":"PHASE1","title":"A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":"Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT03112603","phase":"PHASE3","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-06-29","conditions":"Graft-versus-host Disease (GVHD)","enrollment":330},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT01352312","phase":"PHASE1","title":"Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-05-25","conditions":"Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma","enrollment":10},{"nctId":"NCT02105766","phase":"PHASE2","title":"Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-04-21","conditions":"Sickle Cell Disease, Thalassemia, Stem Cell Transplantation","enrollment":56},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT03077542","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-04-06","conditions":"Sickle Cell Disease","enrollment":57},{"nctId":"NCT00032773","phase":"PHASE1, PHASE2","title":"Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2002-01-30","conditions":"Acute Graft Versus Host Disease","enrollment":36},{"nctId":"NCT00571662","phase":"PHASE2","title":"Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-12-08","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":76},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00074282","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-04-14","conditions":"Leukemia","enrollment":102},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT00496873","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06","conditions":"Lymphoma","enrollment":100},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00074035","phase":"PHASE2","title":"Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-12","conditions":"Graft Versus Host Disease","enrollment":39},{"nctId":"NCT00224874","phase":"PHASE2","title":"Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-09","conditions":"Graft vs Host Disease, Immune System Disorders","enrollment":180},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01460602","phase":"PHASE1, PHASE2","title":"Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2010-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT00096161","phase":"PHASE2","title":"Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-05","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":36},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00602836","phase":"PHASE2","title":"Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-02","conditions":"Leukemia, Lymphoma","enrollment":45},{"nctId":"NCT01239368","phase":"PHASE1, PHASE2","title":"Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-10","conditions":"Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis","enrollment":34},{"nctId":"NCT01362790","phase":"PHASE1, PHASE2","title":"SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-11","conditions":"Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms","enrollment":55},{"nctId":"NCT02032446","phase":"PHASE1, PHASE2","title":"Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2013-09","conditions":"Hematologic Malignancies","enrollment":47},{"nctId":"NCT01416974","phase":"PHASE1","title":"Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-08-22","conditions":"Leukemia","enrollment":13},{"nctId":"NCT00038025","phase":"PHASE2","title":"A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-09-06","conditions":"Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia","enrollment":60},{"nctId":"NCT01024010","phase":"PHASE2","title":"Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia","enrollment":82},{"nctId":"NCT00923845","phase":"PHASE2","title":"Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03-01","conditions":"Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome","enrollment":25},{"nctId":"NCT00541034","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-05","conditions":"Leukemia, Lymphoma","enrollment":49},{"nctId":"NCT00816595","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-02","conditions":"Leukemia, Lymphoma","enrollment":68},{"nctId":"NCT00676806","phase":"PHASE2","title":"A Phase II Study of Umbilical Cord Blood Transplantation","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2005-07","conditions":"Leukemia, Lymphoma, Multiple Myeloma","enrollment":7},{"nctId":"NCT00698685","phase":"PHASE2","title":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2006-01-23","conditions":"Leukemia, Lymphoma, Hodgkin's Disease","enrollment":14},{"nctId":"NCT00201721","phase":"PHASE2","title":"Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2002-07","conditions":"B-Chronic Lymphocytic Leukemia","enrollment":28},{"nctId":"NCT00402714","phase":"PHASE2","title":"A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies","status":"COMPLETED","sponsor":"Yale University","startDate":"2006-07","conditions":"Hematologic Malignancies","enrollment":14},{"nctId":"NCT01681563","phase":"PHASE2","title":"Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Niguarda Hospital","startDate":"2011-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":47},{"nctId":"NCT00254163","phase":"PHASE3","title":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2003-12","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":184},{"nctId":"NCT00546377","phase":"PHASE1, PHASE2","title":"Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-07","conditions":"Leukemia, Lymphoma","enrollment":50},{"nctId":"NCT00201786","phase":"PHASE2","title":"Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2003-07","conditions":"Graft-Versus-Host Disease","enrollment":8},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00506922","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2000-09","conditions":"Leukemia, Lymphoma","enrollment":150},{"nctId":"NCT00669318","phase":"PHASE2","title":"Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-07","conditions":"Leukemia, Lymphoma","enrollment":41},{"nctId":"NCT00496340","phase":"PHASE2","title":"Phase II Trial of Pentostatin and Targeted Busulfan","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-07","conditions":"Hematologic Malignancies","enrollment":42},{"nctId":"NCT01001780","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2009-08","conditions":"Active Chronic Graft Versus Host Disease","enrollment":""},{"nctId":"NCT00003658","phase":"PHASE2","title":"Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-09","conditions":"Leukemia, Lymphoma","enrollment":60},{"nctId":"NCT01188798","phase":"PHASE3","title":"Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":6},{"nctId":"NCT00026351","phase":"PHASE2","title":"Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Pharmatech Oncology","startDate":"2000-12","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00006968","phase":"PHASE1, PHASE2","title":"Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2000-09","conditions":"Kidney Cancer","enrollment":4},{"nctId":"NCT00453193","phase":"PHASE2","title":"Alemtuzumab and Pentostatin In T-cell Neoplasms","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-09","conditions":"Lymphoma, Leukemia","enrollment":26},{"nctId":"NCT00003005","phase":"PHASE1","title":"Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"1997-12","conditions":"Leukemia","enrollment":14},{"nctId":"NCT00049413","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Hoag Memorial Hospital Presbyterian","startDate":"2002-06","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00927797","phase":"PHASE2","title":"Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2005-02","conditions":"Immunocytoma/Morbus Waldenström, B-Cell Non-Hodgkin's Lymphoma, B-Cell Chronic Lymphocytic Leukemia","enrollment":185},{"nctId":"NCT00144430","phase":"PHASE2","title":"Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2004-01","conditions":"Graft vs Host Disease","enrollment":60},{"nctId":"NCT00709215","phase":"PHASE1, PHASE2","title":"Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia","status":"UNKNOWN","sponsor":"OncoVista, Inc.","startDate":"2008-06","conditions":"Refractory TdT-Positive Leukemia","enrollment":44},{"nctId":"NCT00131313","phase":"PHASE4","title":"Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.","status":"UNKNOWN","sponsor":"East Valley Hematology and Oncology Medical Group","startDate":"2003-01","conditions":"Chronic Lymphocytic Leukemia","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Deoxycoformycin","genericName":"Deoxycoformycin","companyName":"Boston Medical Center","companyId":"boston-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deoxycoformycin, also known as pentostatin, is a small molecule inhibitor of the enzyme adenosine deaminase. It is used as an anticancer chemotherapeutic drug, primarily in the treatment of various types of lymphoma and leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}